HLA-A and metastatic colorectal cancer: The efficacy of ATT has been demonstrated in a xenograft mouse model (40) and a metastatic colorectal cancer patient (41) by targeting non-spliced epitopes carrying KRAS G12D mutations and presented by HLA-A*11:01 or -C*08:02 molecules, respectively.